Sun Pharma Q3 Results Review - Inline Performance; Valuations Fair: ICICI Securities

ICICI Securities Report

Sun Pharmaceutical Industries Ltd.’s Q3 FY23 performance was largely in line with our estimates. Consolidated revenue grew 12.9% YoY to Rs 111.4 billion (our estimate: Rs 110.5 billion) driven by U.S. and emerging market sales. Ebitda margin stood at 26.0% (our estimate: 26.6%).

Specialty portfolio grew 10.7% QoQ to $223 million (excluding milestone income) led by growth in Ilumya and Winlevi. India business grew 7.1% YoY supported by growth across therapies.

We remain positive on Sun Pharma’s long-term outlook considering its strong India business, scale up in specialty sales and focus on margin expansion through superior revenue mix and operational efficiency.

The recent acquisition of Concert Pharmaceutical Ltd. reiterates management’s increased focus on its specialty business.

Click on the attachment to read the full report:

More Research Reports On Sun Pharma's Q3 FY23 Results Review

• Performance Largely Inline: Dolat Capital

• Inline Performance; Growth Levers In Place: Systematix

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.